Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?

Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Related Keywords

United States , , Future Treatment Strategies , How Do Practice Patterns Compare , Lower Risk Mds , Lower Risk Myelodysplastic Syndrome , Myelodysplastic Syndrome , Mds , Erythropoietin , Hypomethylating Agents , Growth Factor Support , Erythropoiesis Stimulating Agents , Esa ,